|Free Dividend Report|
|Stock Splits Calendar|
|PVCT Stock Split History|
|Preferred Stock Newsletter|
|Top Option Ideas|
|PVCT Message Board|
PVCT (PVCT) has 1 split in our PVCT split history database. The split for PVCT took place on April 11, 2002. This was a 1 for 300 reverse split, meaning for each 300 shares of PVCT owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 3.33333333333333 share position following the split.
When a company such as PVCT conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the PVCT split history from start to finish, an original position size of 1000 shares would have turned into 3.33333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into PVCT shares, starting with a $10,000 purchase of PVCT, presented on a split-history-adjusted basis factoring in the complete PVCT split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-22.33%|
|Provectus Biopharmaceuticals is a development-stage biopharmaceutical company that is primarily engaged in developing pharmaceuticals for oncology and dermatology indications. Co. focuses on developing its two prescription drug candidates, PV-10 and PH-10. Co. is developing PV-10 for treatment of several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer. Co. is developing PH-10 to provide treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema. All of Co.'s prescription drug candidates are in either the pre-clinical or clinical trial stage. According to our PVCT split history records, PVCT has had 1 split.|
|PVCT Split History Table|
|04/11/2002||1 for 300|
|Healthcare Stock Splits|
|PVCT is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:|